Literature DB >> 23598941

Pigmented villonodular synovitis: dedicated PET imaging findings.

Ian Blake Amber1, Brian J Clark, Gary Stuart Greene.   

Abstract

Pigmented villonodular synovitis (PVNS) is an uncommon entity, which has the potential to cause severe pain. The gold standard for evaluation is MRI, and previous PET findings associated with PVNS have only been documented in the setting of concurrent malignancy. In the setting of recurrent disease, PET is being used to evaluate prebiological and postbiological treatment responses. Recurrent PVNS demonstrates greater hypermetabolic activity than previously documented, supporting the case as a potential mimic of malignant/metastatic disease. Post-treatment evaluations demonstrate decreased metabolic activity, which suggests response to treatment. This behaviour further supports the contention that there is a neoplastic origin to PVNS.

Entities:  

Mesh:

Year:  2013        PMID: 23598941      PMCID: PMC3645251          DOI: 10.1136/bcr-2013-009401

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  Localized nodular synovitis mimicking metastatic melanoma in a patient with metastatic melanoma on whole-body F-18 FDG PET/CT with MRI and pathological correlation.

Authors:  Syed Mahmood; Sofia R Martínez de Llano
Journal:  Clin Nucl Med       Date:  2007-07       Impact factor: 7.794

Review 2.  Malignant giant cell tumor of the tendon sheaths and joints (malignant pigmented villonodular synovitis).

Authors:  F Bertoni; K K Unni; J W Beabout; F H Sim
Journal:  Am J Surg Pathol       Date:  1997-02       Impact factor: 6.394

3.  Incidental detection of pigmented villonodular synovitis on FDG PET.

Authors:  Mehmet T Kitapci; R Edward Coleman
Journal:  Clin Nucl Med       Date:  2003-08       Impact factor: 7.794

4.  Pigmented villonodular synovitis: radiologic-pathologic correlation.

Authors:  Mark D Murphey; John H Rhee; Rachel B Lewis; Julie C Fanburg-Smith; Donald J Flemming; Eric A Walker
Journal:  Radiographics       Date:  2008 Sep-Oct       Impact factor: 5.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.